secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0001437749-23-029657
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar reports tumor reduction in Phase 1b camsirubicin trial for advanced soft tissue sarcoma at CTOS
--------------------------------------------------------------------------------

- 14 patients enrolled across 5 dose cohorts; 9 of 14 had stable disease per RECIST 1.1.
- All patients in cohorts 4 and 5 achieved stable disease; 3 most recent showed ~20% tumor reduction.
- One patient with unresectable cancer became eligible for resection after tumor reduction and underwent successful surgery.
- No dose-limiting toxicity observed; MTD not yet reached; one LVEF decrease in medically complex patient is being monitored.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774923029657/0001437749-23-029657-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774923029657/mnpr20231030_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-029657

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer